P
CRDF icon

Pfizer’s Cardiff Oncology CRDF Stock Holding History

Pfizer’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.74M Hold
2,411,575
– – 1.57% 11
2025
Q4 		$6.78M Hold
2,411,575
– – 2.87% 9
2025
Q3 		$4.97M Hold
2,411,575
– – 1.14% 12
2025
Q2 		$7.6M Hold
2,411,575
– – 1.32% 8
2025
Q1 		$7.57M Hold
2,411,575
– – 1.51% 8
2024
Q4 		$10.5M Buy
+2,411,575
New +$7.54M 0.4% 11

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Pfizer's CRDF Position: Q1 2026 in Review

Pfizer held its Cardiff Oncology (CRDF) position steady in Q1 2026 at 2,411,575 shares worth $3.74M. The position accounts for 1.57% of the portfolio, ranked #11.

Pfizer first reported a position in CRDF in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.5M in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Pfizer held 2,411,575 shares of Cardiff Oncology worth $3.74M as of Q1 2026.
  • Pfizer left its Cardiff Oncology share count unchanged in Q1 2026.
  • Cardiff Oncology made up 1.57% of Pfizer's portfolio in Q1 2026, its #11 holding.
  • Pfizer first reported a position in Cardiff Oncology in Q4 2024 and has held it in 6 quarters since.
  • Pfizer's Cardiff Oncology position peaked at $10.5M in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Pfizer's 13F filing for Q1 2026, filed 12 May 2026.